+ All Categories
Home > Documents > Inequalities in coronary heart disease treatment

Inequalities in coronary heart disease treatment

Date post: 03-Feb-2016
Category:
Upload: fionan
View: 29 times
Download: 0 times
Share this document with a friend
Description:
Inequalities in coronary heart disease treatment. Professor Azeem Majeed University College London. Outline of talk. Why CHD is important Inequalities in CHD Inequalities in treatment Possible explanations Proposed solutions. Why is CHD important?. Mortality: Numbers. - PowerPoint PPT Presentation
Popular Tags:
29
Inequalities in coronary heart disease treatment Professor Azeem Majeed University College London
Transcript
Page 1: Inequalities in coronary heart disease treatment

Inequalities in coronary heart disease treatment

Professor Azeem MajeedUniversity College London

Page 2: Inequalities in coronary heart disease treatment

Outline of talk Why CHD is important Inequalities in CHD Inequalities in treatment Possible explanations Proposed solutions

Page 3: Inequalities in coronary heart disease treatment

Why is CHD important?

Page 4: Inequalities in coronary heart disease treatment

Mortality: Numbers CHD is the single most common cause

of death in both men and women. One in four men and one in six women

die from CHD (about 125,000 deaths in the UK in 2000)

CHD is also the commonest cause of premature death (about 45,000 deaths)

Page 5: Inequalities in coronary heart disease treatment

Mortality: International Death rate from CHD in the UK is

among the highest in the world Although death rates have fallen in

the UK, rates have fallen more quickly in many other countries

Within UK, rates are highest in Scotland, Northern Ireland and Northern England

Page 6: Inequalities in coronary heart disease treatment

Morbidity: Prevalence Calendar year 1998 210 general practices in England &

Wales, part of GPRD 1.3 million patients

Page 7: Inequalities in coronary heart disease treatment

CHD: Prevalence per 1,000

0

50

100

150

200

250

35-44 45-54 55-64 65-74 75-84 85+

MenWomen

Page 8: Inequalities in coronary heart disease treatment

Inequalities in CHD

Page 9: Inequalities in coronary heart disease treatment

Inequalities: Type Social Class Geographical Ethnic Group

Page 10: Inequalities in coronary heart disease treatment

SMR: Social Class Standardised mortality ratios Adjust for age (& sex) Average for population = 100 Values > 100 imply more deaths

than expected Values < 100 imply less deaths

than expected

Page 11: Inequalities in coronary heart disease treatment

SMR: Men by Social Class

020406080

100120140160180200

I I I I I IN II IM IV V

Page 12: Inequalities in coronary heart disease treatment

Prevalence: Area Variations

0

5

10

15

20

25

30

35

40

Q1 Q2 Q3 Q4 Q5

Page 13: Inequalities in coronary heart disease treatment

Inequalities in CHD Treatment

Page 14: Inequalities in coronary heart disease treatment

CHD Treatments Lifestyle changes Drugs for angina Drugs to reduce risk of acute

events: e.g. aspirin & statins Control of risk factors: e.g.

diabetes, high blood pressure Interventions: Angioplasty & CABG

Page 15: Inequalities in coronary heart disease treatment

Age & sex differences Calendar year 1998 210 general practices in England &

Wales, part of GPRD 1.3 million patients

Page 16: Inequalities in coronary heart disease treatment

Statins in CHD Patients

0

10

20

30

40

50

60

35-44 45-54 55-64 65-74 75-84 85+

MenWomen

Page 17: Inequalities in coronary heart disease treatment

Aspirin in CHD Patients

0

10

20

30

40

50

60

70

35-44 45-54 55-64 65-74 75-84 85+

MenWomen

Page 18: Inequalities in coronary heart disease treatment

Statins: Area Variations

0

5

10

15

20

25

30

Q1 Q2 Q3 Q4 Q5

Page 19: Inequalities in coronary heart disease treatment

Study in Wandsworth PCT 63 general practices September 2000 - May 2001 Population 378,000 6778 patients with CHD Some evidence that sex

differences narrowing

Page 20: Inequalities in coronary heart disease treatment

Prescribing in CHD Patients

0

10

20

30

40

50

60

70

Women Men

History of MI &prescribed beta-blockerAngina &prescribed beta-blockerHistory of MI &prescribed ACE-inhibitorPrescribed statin

Prescribed aspirin

Page 21: Inequalities in coronary heart disease treatment

Secondary & Tertiary Care Several studies have examined

equity of access to care Thrombolysis Angiography Angioplasty & CABG Drug treatment on discharge

Page 22: Inequalities in coronary heart disease treatment

Older studies Studies carried out in early - mid

1990s Age, sex and socio-economic

differences present Women, elderly, deprived had

poorer access to specialist investigation & treatment

Page 23: Inequalities in coronary heart disease treatment

SW Thames: Early 1990s Admissions for CHD in one year Proportion of admissions in which

angiography carried out Proportion of admissions in which

coronary artery bypass graft (CABG) or percutaneous transluminal angioplasty (PTCA) carried out

Page 24: Inequalities in coronary heart disease treatment

Admissions with angiography

0

5

10

15

20

25

35-44 45-54 55-64 65-74 75-84 85+

MenWomen

Page 25: Inequalities in coronary heart disease treatment

Admission with CABG/PTCA

0

2

4

6

8

10

12

14

35-44 45-54 55-64 65-74 75-84 85+

MenWomen

Page 26: Inequalities in coronary heart disease treatment

Newer studies Many studies carried out in late

1990s & early 2000s Show a narrowing of gap between

men & women and elderly & younger patients

Possibly still some socio-economic differences in access to specialist care

Page 27: Inequalities in coronary heart disease treatment

Possible Explanations Patient & society Clinical trials Primary care Secondary care Tertiary care

Page 28: Inequalities in coronary heart disease treatment

Proposed solutions Greater awareness among clinicians

and patients More women and elderly in clinical

trials National service frameworks Review of health inequalities Clinical governance Better use of NHS data for monitoring

Page 29: Inequalities in coronary heart disease treatment

Conclusions Even in a free health care system

like the NHS, some groups have poorer access to care than others

Greater awareness among patients, clinicians, policymakers

Interventions in place to reduce inequalities & discrimination


Recommended